Long noncoding RNA DLEU1 aggravates glioma progression via the miR-421/MEF2D axis

Abstract

Background: Long noncoding RNA (lncRNA) deleted in lymphocytic leukemia 1 (DLEU1) was reported to be involved in the development and progression of multiple cancers. However, the accurate expression pattern, biological function and potential molecular mechanism of DLEU1 in glioma are not yet known. The present study investigated the role of DLEU in the development and progression of glioma, as well as the potential mechanism played by DLEU1 in glioma. Materials and methods: The levels of DLEUI in glioma tissues and cell lines were examined using quantitative real-time PCR. The potential effects of DLEU1 on the proliferation, mobility, invasion and apoptosis of glioma cells were evaluated using corresponding in vitro experiments. The association between DLEU1 and microRNA (miR)-421 was also determined using luciferase reporter activity and RNA immunoprecipitation (RIP) assays. Results: The results revealed that DLEU1 was significantly upregulated in glioma tissues and cell lines. Increased DLEU1 was positively associated with the high-grade carcinoma (III-IV). Functional studies revealed that knockdown of DLEU1 expression by siRNA led to decreased proliferation, migration and invasion and increased apoptosis in human glioma cells. Furthermore, luciferase reporter activity and RIP assays confirmed that DLEUI could act as a competing endogenous RNA (ceRNA) for miR-421 that functioned as a tumor suppressor in glioma. Moreover, inhibition miR-421 partially restored the effect of DLEU1 knockdown on the glioma cells. DLEU1 could regulate myocyte enhancer factor 2D (MEF2D) expression, a known target of miR-421 in glioma cells. Conclusion: Taken together, these findings suggested that DLEU1 regulated MEF2D expression to promote glioma progression by sponging miR-421 and that DLEU1 might be a potential therapeutic target for glioma.

CircCPA4 Promotes the Malignant Phenotypes in Glioma via miR-760/MEF2D Axis

“…Recent studies have uncovered the carcinogenic involvement of MEF2D in the outset and development of multiple human cancers, such as pancreatic cancer, osteosarcoma, gastric cancer and so on [33][34][35]. In addition, the tumor-promoting role of MEF2D in glioma development was also documented [36,37]. In the present study, we observed that MEF2D overexpression attenuated the anti-tumor action of miR-760 on glioma progression.…”

<p>SP1-Mediated Upregulation of lncRNA LINC01614 Functions a ceRNA for miR-383 to Facilitate Glioma Progression Through Regulation of ADAM12</p>

“…For instance, increased lncRNA DLEU1 was observed in glioma patients with advanced stages and promoted the proliferation and migration in tumor cells via modulating miRNA-421/ MEF2D axis. 25 LncRNA FOXD2-AS1 was shown to be highly expressed in glioma and its forced expression promoted the metastasis ability of tumor cells via targeting miRNA-185-5p/CCND2 axis. 26 Recently, LINC01614 was found to display its oncogenic roles in lung cancer by regulating miR-217, which suggested the potential tumorrelated effects of LINC01614 in tumorigenesis.…”

LncRNA DLX6-AS1 aggravates the development of ovarian cancer via modulating FHL2 by sponging miR-195-5p

“…The RIP assay was consistent with the description mentioned previously [28]. Imprint ® RNA Immunoprecipitation kit (Sigma, St. Louis, MO, USA) was used for RIP assay.…”